Tarja Alakoski
Overview
Explore the profile of Tarja Alakoski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
196
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Elmadani M, Raatikainen S, Mattila O, Alakoski T, Piuhola J, Astrom P, et al.
Toxicol Rep
. 2023 May;
10:521-528.
PMID: 37152411
Dasatinib is a multitargeted kinase inhibitor used for treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. Unfortunately, treatment of cancer patients with some kinase inhibitors has been associated with...
2.
Halmetoja E, Nagy I, Szabo Z, Alakoski T, Yrjola R, Vainio L, et al.
FASEB J
. 2022 Sep;
36(10):e22544.
PMID: 36098469
Wnt11 regulates early cardiac development and left ventricular compaction in the heart, but it is not known how Wnt11 regulates postnatal cardiac maturation and response to cardiac stress in the...
3.
Vainio L, Taponen S, Kinnunen S, Halmetoja E, Szabo Z, Alakoski T, et al.
Int J Mol Sci
. 2021 Dec;
22(24).
PMID: 34948382
Prior studies show that glycogen synthase kinase 3β (GSK3β) contributes to cardiac ischemic injury and cardiac hypertrophy. GSK3β is constitutionally active and phosphorylation of GSK3β at serine 9 (S9) inactivates...
4.
Paavola J, Alakoski T, Ulvila J, Kilpio T, Siren J, Perttunen S, et al.
EBioMedicine
. 2020 Jan;
51:102608.
PMID: 31911272
Background: Vascular endothelial zinc finger 1 (Vezf1) is a transcription factor previously shown to regulate vasculogenesis and angiogenesis. We aimed to investigate the role of Vezf1 in the postnatal heart....
5.
Vainio L, Szabo Z, Lin R, Ulvila J, Yrjola R, Alakoski T, et al.
JACC Basic Transl Sci
. 2019 Mar;
4(1):83-94.
PMID: 30847422
Myocardial infarction (MI)-induced cardiac fibrosis attenuates cardiac contractile function, and predisposes to arrhythmias and sudden cardiac death. Expression of connective tissue growth factor (CTGF) is elevated in affected organs in...
6.
Magga J, Vainio L, Kilpio T, Hulmi J, Taponen S, Lin R, et al.
Mol Ther
. 2019 Feb;
27(3):600-610.
PMID: 30765322
Activin A and myostatin, members of the transforming growth factor (TGF)-β superfamily of secreted factors, are potent negative regulators of muscle growth, but their contribution to myocardial ischemia-reperfusion (IR) injury...
7.
Alakoski T, Ulvila J, Yrjola R, Vainio L, Magga J, Szabo Z, et al.
Basic Res Cardiol
. 2019 Jan;
114(2):7.
PMID: 30635790
Sprouty1 (Spry1) is a negative modulator of receptor tyrosine kinase signaling, but its role in cardiomyocyte survival has not been elucidated. The aim of this study was to investigate the...
8.
Perjes A, Kilpio T, Ulvila J, Magga J, Alakoski T, Szabo Z, et al.
Basic Res Cardiol
. 2015 Nov;
111(1):2.
PMID: 26611206
The G protein-coupled apelin receptor regulates important processes of the cardiovascular homeostasis, including cardiac development, cardiac contractility, and vascular tone. Most recently, a novel endogenous peptide ligand for the apelin...
9.
Szabo Z, Magga J, Alakoski T, Ulvila J, Piuhola J, Vainio L, et al.
Hypertension
. 2014 Apr;
63(6):1235-40.
PMID: 24688123
Connective tissue growth factor (CTGF) is involved in the pathogenesis of various fibrotic disorders. However, its role in the heart is not clear. To investigate the role of CTGF in...
10.
Kaikkonen L, Magga J, Ronkainen V, Koivisto E, Perjes A, Chuprun J, et al.
J Mol Cell Cardiol
. 2013 Dec;
67:86-93.
PMID: 24361238
cAMP-dependent protein kinase (PKA) regulates the L-type calcium channel, the ryanodine receptor, and phospholamban (PLB) thereby increasing inotropy. Cardiac contractility is also regulated by p38 MAPK, which is a negative...